KR20210043637A - 재발성 여포성 림프종의 치료 - Google Patents

재발성 여포성 림프종의 치료 Download PDF

Info

Publication number
KR20210043637A
KR20210043637A KR1020217007422A KR20217007422A KR20210043637A KR 20210043637 A KR20210043637 A KR 20210043637A KR 1020217007422 A KR1020217007422 A KR 1020217007422A KR 20217007422 A KR20217007422 A KR 20217007422A KR 20210043637 A KR20210043637 A KR 20210043637A
Authority
KR
South Korea
Prior art keywords
compound
mixture
pharmaceutically acceptable
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217007422A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 피 골드
Original Assignee
메이 파마, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메이 파마, 아이엔씨. filed Critical 메이 파마, 아이엔씨.
Publication of KR20210043637A publication Critical patent/KR20210043637A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217007422A 2018-08-14 2019-08-13 재발성 여포성 림프종의 치료 Ceased KR20210043637A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862718926P 2018-08-14 2018-08-14
US62/718,926 2018-08-14
US201962836507P 2019-04-19 2019-04-19
US62/836,507 2019-04-19
PCT/US2019/046408 WO2020036997A1 (en) 2018-08-14 2019-08-13 Treatment of relapsed follicular lymphoma

Publications (1)

Publication Number Publication Date
KR20210043637A true KR20210043637A (ko) 2021-04-21

Family

ID=69525835

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217007422A Ceased KR20210043637A (ko) 2018-08-14 2019-08-13 재발성 여포성 림프종의 치료

Country Status (14)

Country Link
US (1) US20210196725A1 (enExample)
EP (1) EP3836936A4 (enExample)
JP (1) JP2021534116A (enExample)
KR (1) KR20210043637A (enExample)
CN (1) CN112839659A (enExample)
AU (1) AU2019321526A1 (enExample)
BR (1) BR112021002734A2 (enExample)
CA (1) CA3109377A1 (enExample)
IL (1) IL280721A (enExample)
MA (1) MA53237A (enExample)
MX (1) MX2021001765A (enExample)
SG (1) SG11202101417XA (enExample)
TW (1) TW202021593A (enExample)
WO (1) WO2020036997A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. COMBINATION THERAPY
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919869B1 (fr) * 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CN107501241B (zh) * 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
UA116544C2 (uk) * 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
MA38462A1 (fr) * 2013-04-08 2017-10-31 Bayer Pharma AG Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes
CA2979671C (en) * 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
MX2020001727A (es) * 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Also Published As

Publication number Publication date
WO2020036997A1 (en) 2020-02-20
US20210196725A1 (en) 2021-07-01
CA3109377A1 (en) 2020-02-20
MX2021001765A (es) 2021-04-19
BR112021002734A2 (pt) 2021-07-20
TW202021593A (zh) 2020-06-16
EP3836936A4 (en) 2022-05-18
CN112839659A (zh) 2021-05-25
IL280721A (en) 2021-03-25
SG11202101417XA (en) 2021-03-30
JP2021534116A (ja) 2021-12-09
AU2019321526A1 (en) 2021-03-25
EP3836936A1 (en) 2021-06-23
MA53237A (fr) 2021-06-23

Similar Documents

Publication Publication Date Title
EP4146647B1 (en) Cdk inhibitors
KR102477960B1 (ko) 항증식성 화합물 및 이의 사용 방법
CN111909173B (zh) 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
JP2021517116A (ja) 併用療法
US11351176B2 (en) Combination therapy
CN112739420A (zh) 苯氧基-吡啶基-嘧啶化合物及使用方法
US20210196725A1 (en) Treatment of relapsed follicular lymphoma
WO2020132563A1 (en) Combination therapy
KR20210043635A (ko) B 세포 악성 종양의 치료
JP2021534114A (ja) 併用療法
CN120813352A (zh) Dgk（二酰基甘油激酶）抑制剂的组合
AU2015240094B2 (en) Combinations of cancer therapeutics
HK40042521A (en) Benzoxazepin oxazolidinone compounds and methods of use
HK40042000A (en) Benzoxazepin oxazolidinone compounds and methods of use
HK40051446A (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use
HK1254517A1 (zh) 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210311

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220811

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250317

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250522

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D